Drug Trial News

RSS

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx Therapeutics announced today that clinical study results confirm that the primary site of action of Type 2 diabetes medicine metformin is in the lower bowel rather than in the circulation.

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada.

24 Jun 2013

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.

24 Jun 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5.

21 Jun 2013

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

One of the largest clinical trials done in infants with congenital (present at birth) heart diseases, published in the New England Journal of Medicine, shows that the increasingly common practice of using the drug clopidogrel (Plavix-) to reduce shunt-related blood flow issues is not effective in the dose studied.

21 Jun 2013

BerGenBio AS starts Phase 1 Clinical Trial for BGB324 oral AXL inhibitor

BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.

20 Jun 2013

EORTC starts phase 2 trial in elderly patients with HER-2 positive metastatic breast cancer

Despite the fact that the incidence of cancer is many fold higher in persons over 65 years of age, we still have an inadequate understanding on how best to treat these older cancer patients. Furthermore, even though elderly patients are occasionally included in clinical trials, those elderly patients who are eventually included are mostly 'healthy' (fit) elderly patients.

20 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

20 Jun 2013

Results of ibrutinib Phase 2 study in patients with mantle cell lymphoma published in NEJM

Pharmacyclics, Inc. today announced that The New England Journal of Medicine published results of a Phase 2 study evaluating the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed/refractory mantle cell lymphoma online.

20 Jun 2013

Researchers shed light on how rice blast fungus invades plant tissue

Like a stealthy enemy, blast disease invades rice crops around the world, killing plants and cutting production of one of the most important global food sources.

19 Jun 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.

19 Jun 2013

Patient enrollment and trial duration heavily impact the total cost of Phase 1 oncology trial

Both the number of patients and trial duration heavily impact a Phase 1 oncology trial's total cost. The underlying force driving most costs is patient enrollment. As the time to reach full enrollment increases, the trial lasts longer and the cost of maintaining and staffing clinical sites rises.

19 Jun 2013

TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

TWi Biotechnology, Inc. announced that it has completed the patient enrollment in a phase II trial of AC-201 for Gout Flare Prophylaxis during urate-lowering therapy. This randomized, double-blind, placebo-controlled Phase II study is conducted in 8 major medical centers in Taiwan.

18 Jun 2013

Vanda presents additional data from tasimelteon Phase III studies at ENDO 2013

Vanda Pharmaceuticals Inc. presented additional data today at ENDO 2013, the Endocrine Society's 95th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and cortisol rhythms.

18 Jun 2013

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

UT Southwestern Medical Center researchers are seeking 150 adults with type 2 diabetes to take part in the local arm of a major national clinical trial that will compare benefits and side effects of four widely used therapies to lower blood-sugar levels.

18 Jun 2013

Drug Trial News

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

BerGenBio AS starts Phase 1 Clinical Trial for BGB324 oral AXL inhibitor

EORTC starts phase 2 trial in elderly patients with HER-2 positive metastatic breast cancer

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

Results of ibrutinib Phase 2 study in patients with mantle cell lymphoma published in NEJM

Researchers shed light on how rice blast fungus invades plant tissue

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Patient enrollment and trial duration heavily impact the total cost of Phase 1 oncology trial

TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

Vanda presents additional data from tasimelteon Phase III studies at ENDO 2013

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News